EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Oct 26, 2026
Excerpt: 10 signals (from 13 total). Healthcare leads (5). price range $12-$173. 1 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
Equity markets are displaying broad-based strength on October 26, 2026, with all three major indices posting gains and the tech-heavy Nasdaq leading the advance at +0.82%. This risk-on posture suggests healthy institutional participation and a favorable backdrop for momentum-oriented strategies. The across-the-board buying indicates this is not a narrow or speculative rally, which generally improves the reliability of technical reclaim setups like dip_bounce_v2_reclaim, where price recovering above key levels tends to follow through more consistently when broader market conditions are supportive.
The VIX at 18.39, down sharply by -5.45%, is a particularly meaningful data point for this signal type. Elevated but declining volatility sits in a sweet spot for dip-bounce strategies — there is still enough intraday range to generate meaningful price swings off support levels, yet the compression in fear readings suggests sellers are losing conviction. This environment reduces the risk of false reclaims being immediately reversed by panic-driven selling, improving the signal-to-noise ratio for entries built around price reclaiming short-term technical levels.
Healthcare's emergence as the top sector among today's 13 signals adds an interesting layer of context. Healthcare tends to attract defensive rotation when investors seek growth with lower cyclical risk, and its leadership during a broadly positive tape suggests sector rotation may be favoring quality and stability alongside the broader risk appetite. Traders monitoring dip-bounce setups in this sector should note that defensive sector leadership can produce steadier, if less explosive, follow-through compared to high-beta sectors — making position sizing and realistic target-setting especially important.
📊 Signals (10 of 13 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | RHI | Robert Half Inc. | Industrials | $44.98 | 0.27 | — | $4.6B |
| 2 | WFG | West Fraser Timber Co.... | Basic Materials | $70.00 | 0.24 | — | $5.3B |
| 3 | BHVN | Biohaven Ltd. | Healthcare | $14.45 | 0.21 | — | $2.2B |
| 4 | KFRC | Kforce Inc. | Industrials | $58.42 | 0.20 | — | $1.0B |
| 5 | DOC | Healthpeak Properties,... | Real Estate | $19.36 | 0.15 | — | $13.3B |
| 6 | NEOG | Neogen Corporation | Healthcare | $12.21 | 0.14 | — | $2.7B |
| 7 | GH | Guardant Health, Inc. | Healthcare | $173.25 | 0.11 | — | $23.2B |
| 8 | CURB | Curbline Properties Corp. | Real Estate | $28.43 | 0.10 | — | $3.5B |
| 9 | HNI | HNI Corporation | Industrials | $47.70 | 0.09 | — | $3.4B |
| 10 | NGL | NGL Energy Partners LP | Energy | $15.90 | 0.09 | — | $2.0B |
Recent Headlines
BHVN (Biohaven Ltd.)
- Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
- Biohaven presents preclinical data on kidney disease drug candidate
CURB (Curbline Properties Corp.)
- REITs Rebound As Earnings Deliver
KFRC (Kforce Inc.)
- Kforce Inc. (KFRC) Q3 2026 Earnings Call Transcript
- Kforce (KFRC) Q3 Earnings and Revenues Surpass Estimates
- Kforce Reports Third Quarter 2026 Revenue of $357.8 Million, Exceeding High-End of Guidance, and Improving 7.5% Year Over Year
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.